Symposium NGS 2016

Introduction of Next-Generation-Sequencing technology in (hemato-)oncology in the Belgian health care system.

The use of Next generation sequencing technology in routine analyses carried out as part of our healthcare system represents a major step forward. In Belgium, the introduction of this technology in (haemato-)oncology is being developed in a 5-year national pilot project coordinated by the PSI Cancer Centre, a project launched in January 2016.

Program

09.30h - 10.15h : Welcome 
10.30h — 12.30h : Introduction of NGS in (haemato)oncology in Belgium
 

• Introductie NL — M. Van Den Bulcke, WIV-ISP
• Commission Personalized Medicine (EN) — M. Van Den Bulcke, WIV-ISP
• Platform CRM — TMC: a link procedure for companion reimbursement (EN) — ​A. Waeytens, RIZIV-INAMI
• Guidelines ‘NGS in (hemato-)oncology’ NGS genepanel testing (EN) — A. Hébrant, WIV-ISP
• Benchmarking trial and EQA NGS in (hemato-)oncology (EN) — V. Ghislain, WIV-ISP
• Patient participation: Focus group (EN) -​ K. Moens, WIV-ISP
• Healthdata Datamanagement for NGS (EN) -​ J. Van Bussel, WIV-ISP
• Accreditation of NGS within ISO 15189​ (EN) -​ E. Van Rossen, SPF Economie

12.30h — 13.30h : Lunch
13.30h — 16.00h : “Genomics in oncology and hematology: opportunities & challenges
 

• “Precision”: Bringing innovation to the patient (EN) — ​​J. De Grève​, Vrije Universiteit Brussel, Bruxelles, Belgique
• JARC: Joint Action Rare cancers (EN) — A. Trama, Instituto Nationale di Tumori, Milan, Italie
• Impact on current and future cancer​​ immunotherapies (EN) — ​ K. Vermaelen, UGent, Gand, Belgique
• ​​Liquid biopsies (EN) — ​S. Tejpar​, KU Leuven, Louvain, Belgique
• ​NGS for oncogenetics (EN) -​ M. Abramowicz, Université Libre de Bruxelles, Bruxelles, Belgique
• Comprehensive Genomic Profiling with FMI — bringing value to patients (EN) — V​​. Natarajan, Foundation Medicine, Europe

16.00h — 17.30h : Reception

Related Projects

• Commission de Médecine Personnalisée (ComPerMed)
• ComPerMed — Next-Generation Sequencing in hemato(-oncology)
• Focus Groups: Information Needs and Attitudes of Cancer Patients to NGS Testing (FR)